Alendronate for Effective Treatment of Male Osteoporosis : An Insight

被引:0
作者
Al Lawati, Hanan [1 ]
Al Busaidi, Sara [2 ]
Al Rawahi, Thuraiya [3 ]
Al Lawati, Abdullah [4 ]
Kifah, Ahmed [5 ]
Das, Srijit [6 ]
机构
[1] Oman Coll Hlth Sci, Dept Pharmaceut, Pharm Program, Muscat, Oman
[2] Sultan Qaboos Univ, Muscat, Oman
[3] Royal Coll Surg Ireland Bahrain, Muharraq, Bahrain
[4] Sultan Qaboos Univ Hosp, Muscat, Oman
[5] Natl Univ, Sohar, Oman
[6] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Human & Clin Anat, Muscat, Oman
关键词
Alendronate; drug; osteoporosis; male; skeletal; bone; BONE-MINERAL DENSITY; VERTEBRAL FRACTURE RISK; ZOLEDRONIC ACID; PARATHYROID-HORMONE; DOUBLE-BLIND; IN-VITRO; BISPHOSPHONATES; MEN; WOMEN; PREVALENCE;
D O I
10.2174/0113816128310838240820065324
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males. Various drugs, such as nitrogen-containing phosphonates, RANK ligand inhibitors, parathormones, and alendronate, have been used for effective treatment of osteoporosis. Alendronate (alendronic acid), a nitrogen-containing bisphosphonate that inhibits bone resorption by osteoclasts, was synthesized during the 1970s. In the present review, we discuss the pharmacokinetics, mechanism of action, adverse effects, contraindications, and toxicity monitoring of alendronate. The drug may be effectively used for the treatment of male osteoporosis in order to increase bone mineral density and prevent fractures.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 141 条
  • [2] Ahn Seong Hee, 2020, J Bone Metab, V27, P281, DOI 10.11005/jbm.2020.27.4.281
  • [3] Al Saleh Jamal, 2016, Oman Med J, V31, P117, DOI 10.5001/omj.2016.23
  • [4] Aoki T T, 2000, Endocr Pract, V6, P127
  • [5] Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men
    Avenell, Alison
    Mak, Jenson C. S.
    O'Connell, Dianne
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (04):
  • [6] Babhulkar S., 2021, INT J RES ORTHOP, V7, P362, DOI [10.18203/issn.2455-4510.IntJResOrthop20210630, DOI 10.18203/ISSN.2455-4510.INTJRESORTHOP20210630]
  • [7] Vertebral fracture risk and impact of database selection on identifying elderly Lebanese with osteoporosis
    Baddoura, Rafic
    Arabi, Asma
    Haddad-Zebouni, Souha
    Khoury, Nabil
    Salamoun, Mariana
    Ayoub, Ghazi
    Okais, Jad
    Awada, Hassane
    El-Hajj Fuleihan, Ghada
    [J]. BONE, 2007, 40 (04) : 1066 - 1072
  • [8] The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate
    Bajaj, Devendra
    Geissler, Joseph R.
    Allen, Matthew R.
    Burr, David B.
    Fritton, J. C.
    [J]. BONE, 2014, 64 : 57 - 64
  • [9] Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate
    Bala, Yohann
    Farlay, Delphine
    Chapurlat, Roland D.
    Boivin, Georges
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 165 (04) : 647 - 655
  • [10] Acute Localized Exanthematous Pustulosis Due to Alendronate
    Bautista-Villanueva, S.
    Galleani, C.
    Barranco, R.
    Bellon, T.
    Blanco, M.
    Garcia-Moguel, I
    [J]. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2022, 32 (01) : 69 - 70